Abstract:Abstract Background: The oxaliplatin-based chemotherapy has revealed an encouraging therapeutic efficacy for advanced hepatocellular carcinoma patients. However, the development of resistance limits its clinical utilization. In addition, the chemotherapy resistance in HCC is usually accompanied with other malignant phenotypes, such as cell proliferation and metastasis, which together result in poor prognosis of HCC patients. Therefore, efforts should be made to explore potential regulators which fuel multiple events of HCC progression.Methods: The qRT-PCR, western blot, immunohistochemistry and immunofluorescence were performed to measure mRNA and protein expression. MTT assay, colony formation and Transwell assay were performed to evaluate cell proliferation and metastasis. Flow cytometry was performed to test cell apoptosis. Alkaline Comet assay was performed to measure DNA lesions. Transmission electron microscope analysis provided potent testimony of autophagy. The role of HN1 on the malignant phenotypes of hepatoma carcinoma was demonstrated in vitro and in vivo.Results: The immunohistochemistry analysis of HCC patient tissues revealed that the expression of HN1 was higher in HCC tissues compared to adjacent tissues and was associated with worse prognosis. In vitro, HN1 knockdown inhibited proliferation and metastasis of HCC cells, whereas HN1 overexpression promoted their proliferation and metastasis. In addition, we found that HN1 knockdown sensitized HCC cells to oxaliplatin, which is companied with deteriorated DNA damage and increased cell apoptosis in oxaliplatin-treated HCC cells. In vivo, HN1 knockdown inhibited the tumor growth and metastasis, and promoted the anti-cancer efficiency of oxaliplatin. Mechanically, HN1 prevented HMGB1 from ubiquitination and degradation via autophagy-lysosome pathway, which is related to its interaction with TRIM28, and overexpression of HMGB1 can restore the malignant phenotypes of HN1 knockdown in HCC cells. Furthermore, we found that HN1 can regulate cellular autophagy via HMGB1, which is important to tumor-promoting effect of HN1.Conclusions: In conclusion, we systemically revealed the multiple functions of HN1 in HCC progression and the underlying molecular mechanism, which indicated that HN1 could be a promising therapeutic target for HCC treatment.

The role and mechanisms of NCX1 on proliferation and invasion of hepatocellular carcinoma

The Role of Mir-99B in Mediating Hepatocellular Carcinoma Invasion and Migration.

Biological functions and clinical applications of exosomal non-coding RNAs in hepatocellular carcinoma

MNS1 Promotes Hepatocarcinogenesis and Metastasis Via Activating PI3K/AKT by Translocating Β‐catenin and Predicts Poor Prognosis

Comprehensive analysis of the role of netrin G1 (NTNG1) in hepatocellular carcinoma cells.

Effect of neurotensin/interleukin-8/CXC chemokine ligand 1 signaling on the cancer stem-like phenotype and invasive and metastatic ability of hepatocellular carcinoma and action mechanism

Non-SMC condensin I complex subunit H enhances proliferation, migration, and invasion of hepatocellular carcinoma.

Discovery of NKCC1 as a potential therapeutic target to inhibit hepatocellular carcinoma cell growth and metastasis.

Expression and Modulation of Na(+) /H(+) Exchanger 1 Gene in Hepatocellular Carcinoma: A Potential Therapeutic Target.

Panx1 Promotes Invasion-Metastasis Cascade in Hepatocellular Carcinoma

HAX-1 Promotes the Migration and Invasion of Hepatocellular Carcinoma Cells Through the Induction of Epithelial-Mesenchymal Transition Via the NF-κB Pathway.

Over-expression of Na + /H + exchanger 1 and its clinicopathologic significance in hepatocellular carcinoma

HN1 Promotes Proliferation, Metastasis and Attenuates the Chemosensitivity of HCC Cells to Oxaliplatin by Inhibiting Degradation of HMGB1 Through Interacting with TRIM28

Suppression of Heterogeneous Nuclear Ribonucleoprotein C Inhibit Hepatocellular Carcinoma Proliferation, Migration, and Invasion via Ras/MAPK Signaling Pathway

NR1D2 Accelerates Hepatocellular Carcinoma Progression by Driving the Epithelial-to-Mesenchymal Transition

CXCR2/CXCL5 axis contributes to epithelial-mesenchymal transition of HCC cells through activating PI3K/Akt/GSK-3β/Snail signaling.

Overexpression of Non-Smc Condensin I Complex Subunit G Serves As a Promising Prognostic Marker and Therapeutic Target for Hepatocellular Carcinoma

HN1L-mediated Transcriptional Axis AP-2γ/METTL13/TCF3-ZEB1 Drives Tumor Growth and Metastasis in Hepatocellular Carcinoma.

The HN1/HMGB1 Axis Promotes the Proliferation and Metastasis of Hepatocellular Carcinoma and Attenuates the Chemosensitivity to Oxaliplatin

CXCR2/CXCL5 Axis Contributes to Epithelial–mesenchymal Transition of HCC Cells Through Activating PI3K/Akt/GSK-3β/Snail Signaling

Overexpression of Chemokine (C-X-C) Ligand 1 (cxcl1) Associated with Tumor Progression and Poor Prognosis in Hepatocellular Carcinoma